Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL. These agents include monoclonal antibodies to CD19 (Amgen’s Blincyto) and CD20 (Roche/Genentech’s Rituxan/MabThera); new drugs for T-cell ALL (e.g., Novartis’s Arranon); and TKI agents for Philadelphia chromosome-positive (Ph+) ALL (e.g., Novartis’s Gleevec, BMS’s Sprycel, Ariad Pharmaceutical’s Iclusig). Nonetheless, chemotherapies remain the backbone of first-line treatment for ALL. Targeted agents in development—including novel kinase inhibitors, proteasome inhibitors, and immunomodulatory agents, such as chimeric antigen receptor T-cell (CAR-T) therapies—hold promise of providing ALL patients with additional treatment options.
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Six country-specific interviews with thought leaders (medical oncologist-hematologists).
Epidemiology: Diagnosed incident cases of ALL subpopulations; clinical and market-relevant drug-treatable populations.
Population segments in market forecast: First-line adult and pediatric ALL; relapsed/refractory adult and pediatric ALL.
Emerging therapies: Phase III: 3 drugs; Phase II: 3 drugs.
Product Description: Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.